Results 71 to 80 of about 2,875 (114)

Baseline MRI markers and clinical outcomes during anti-amyloid β therapy: A real-world study in a Japanese dementia center. [PDF]

J Prev Alzheimers Dis
Kujuro Y, Saito M, Maruko M, Kamiyama K, Nakano A, Qian E, Okamura T, Ito D, Kageyama T, Sugiyama I, Ishihara E, Kuwahara T, Moritani K, Katai H, Hattori H.   +14 more
europepmc   +1 more source

Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review. [PDF]

J Clin Med
Kalampokini S, Keramidiotis I, Frontistis A, Zuchi F, Michmizos D, Papaliagkas V, Koutsouraki E.   +6 more
europepmc   +1 more source

Regional amyloid-PET clearance dynamics and anti-Aβ monoclonal antibody therapy: a preliminary real-world study. [PDF]

Alzheimers Dement (Amst)
Ghirelli A, Cecchetti G, Spinelli EG, Samanes Gajate AM, Rugarli G, Pisano S, Zamboni IAL, Canu E, Castelnovo V, Sibilla E, Gilioli A, Tripodi C, Freri F, Panzacchi A, Pepe G, Chiti A, Filippi M, Agosta F.   +17 more
europepmc   +1 more source

Further data to address the Alzheimer's coverage with evidence development questions. [PDF]

Alzheimers Dement
Boustani M, Klein EG, Zimmer JA, Wang H, Engle SE, Phipps A, Japha M, Schilling T, Hartry A, Alzheimer's Disease Neuroimaging Initiative.   +9 more
europepmc   +1 more source

Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics. [PDF]

Eur J Neurol
Rosenberg A, Rennie A, Ekman U, Daniilidou M, Hall A, Matton A, Solomon A, Wahlund LO, Kivipelto M, Westman E.   +9 more
europepmc   +1 more source

From trial population to treated population: why EU-eligible subgroup analyses matter for anti-amyloid immunotherapy. [PDF]

J Prev Alzheimers Dis
Grimmer T.
europepmc   +1 more source

Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease. [PDF]

Alzheimers Dement
Collins EC, Lu M, Beck R, Hendrix J, Hodsdon ME, Hansson O.   +5 more
europepmc   +1 more source

Therapeutic Time Window of Disease-Modifying Therapy for Early Alzheimer's Disease in Japanese Individuals: Analysis Based on J-ADNI Study. [PDF]

Geriatr Gerontol Int
Nakashima S, Sato K, Niimi Y, Ihara R, Suzuki K, Iwata A, Satake W, Iwatsubo T, Japanese Alzheimer's Disease Neuroimaging Initiative.   +8 more
europepmc   +1 more source

Sustaining Drug Discovery Amid the Limits of Alzheimer's Disease Immunotherapies. [PDF]

eNeuro
McDiarmid A.
europepmc   +1 more source

Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study. [PDF]

Jpn J Radiol
Otomi Y, Shinya T, Otsuka H, Kasai H, Matsushita T, Takaoka Y, Hiroshima Y, Matsubara T, Fujita K, Tomioka Y, Nakataki M, Numata S, Izumi Y, Harada M.   +13 more
europepmc   +1 more source